1. The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome.
- Author
-
Kiaco K, Rodrigues AS, do Rosário V, Gil JP, and Lopes D
- Subjects
- ATP Binding Cassette Transporter, Subfamily B genetics, ATP Binding Cassette Transporter, Subfamily B metabolism, Angola, Antimalarials pharmacokinetics, Artemether, Lumefantrine Drug Combination, Artemisinins pharmacokinetics, Cytochrome P-450 CYP3A genetics, Cytochrome P-450 CYP3A metabolism, Drug Combinations, Ethanolamines pharmacokinetics, Fluorenes pharmacokinetics, Humans, Prevalence, Recurrence, Treatment Outcome, Antimalarials pharmacology, Artemisinins pharmacology, Ethanolamines pharmacology, Fluorenes pharmacology, Genotype, Malaria drug therapy, Polymorphism, Single Nucleotide
- Abstract
Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.
- Published
- 2017
- Full Text
- View/download PDF